GSK and Pfizer launch ViiV Healthcare
The joint venture (JV), which was formed by GlaxoSmithKline (GSK) and Pfizer in April, has rights to a portfolio of 10 HIV treatments, including Epzicom and Selzentry which generated combined revenues of £1.6bn (€1.8bn) in 2008.
ViiV also has seven candidate HIV treatments in development, five opf which are being examined in Phase II trials.
Dominique Limet, CEO of the new firm, explained that: “[ViiV’s] R&D efforts, strategic partnerships and licensing opportunities will be focussed on delivering medications that help address resistance issues and dosing complexity."
Dr Limet stressed that the firm’s R&D efforts “will not solely focus on creating ‘new’ medicines,” adding that it will explore the broader potential of all of the molecules in its portfolio.
